Shenyang Xingqi Pharmaceutical Co., Ltd. Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Million

Consolidate Quarterly Results

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Jun'24

Mar'24

Net Sales

740.99

626.60

536.14

504.10

547.49

534.09

345.82

Other Operating Income

0.00

Total Operating income

740.99

626.60

536.14

504.10

547.49

534.09

345.82

Raw Material Cost

130.77

127.99

116.08

119.09

125.51

120.25

92.74

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

1.00

1.30

1.50

1.65

1.80

1.66

0.61

Selling and Distribution Expenses

234.04

233.48

199.82

233.92

220.65

219.97

181.36

Other Expenses

6.24

3.96

4.18

7.65

5.60

3.60

3.45

Total Expenditure (Excl Depreciation)

428.17

402.40

359.21

431.16

403.93

377.88

309.20

Operating Profit (PBDIT) excl Other Income

312.8

224.20000000000002

176.9

72.9

143.6

156.2

36.6

Other Income

2.98

-5.85

16.15

-8.15

5.01

7.61

3.88

Operating Profit (PBDIT)

305.07

235.14

205.70

85.27

165.80

186.65

68.59

Interest

1.00

1.30

1.50

1.65

1.80

1.66

0.61

Exceptional Items

0.00

Gross Profit (PBDT)

610.22

498.61

420.06

385.01

421.98

413.84

253.07

Depreciation

0.00

26.66

26.46

26.33

Profit Before Tax

304.06

207.17

177.53

57.17

137.53

158.67

41.66

Tax

39.98

18.24

31.64

9.87

16.09

24.10

6.91

Provisions and contingencies

0.00

Profit After Tax

264.08

188.93

145.90

47.30

121.44

134.57

34.75

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

264.08

188.93

145.90

47.30

121.44

134.57

34.75

Share in Profit of Associates

0.00

Minority Interest

0.00

Other related items

0.00

Consolidated Net Profit

264.08

188.93

145.90

47.30

121.44

134.57

34.75

Equity Capital

0.00

Face Value

1.0

Reserves

1,857.29

1,758.16

1,743.26

1,593.17

1,627.76

1,504.08

1,736.67

Earnings per share (EPS)

1.08

0.77

0.59

0.19

0.5

0.55

0.14

Diluted Earnings per share

1.08

0.77

0.59

0.19

0.5

0.55

0.14

Operating Profit Margin (Excl OI)

40.77%

34.2%

30.38%

13.28%

24.53%

28.59%

11.1%

Gross Profit Margin

41.04%

37.32%

38.09%

16.59%

29.95%

34.64%

19.66%

PAT Margin

35.64%

30.15%

27.21%

9.38%

22.18%

25.2%

10.05%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - YoY

Net Sales

YoY Growth in quarter ended Sep 2025 is 35.34% vs 30.54% in Sep 2024

Consolidate Net Profit

YoY Growth in quarter ended Sep 2025 is 117.55% vs 28.33% in Sep 2024

Operating Profit (PBDIT) excl Other Income

YoY Growth in quarter ended Sep 2025 is 87.87% vs 24.94% in Sep 2024

Interest

YoY Growth in quarter ended Sep 2025 is -44.44% vs 260.00% in Sep 2024

Operating Profit Margin (Excl OI)

YoY Growth in quarter ended Sep 2025 has improved from Sep 2024

Compare Quarterly Results Of Shenyang Xingqi Pharmaceutical Co., Ltd. With

Select Peers

Figures in Million

Consolidate Quarterly Results

Change(CNY)

Change(%)

Net Sales

740.99

Other Operating Income

0.00

Total Operating income

740.99

Raw Material Cost

130.77

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

1.00

Selling and Distribution Expenses

234.04

Other Expenses

6.24

0.00

6.24

Total Expenditure (Excl Depreciation)

428.17

Operating Profit (PBDIT) excl Other Income

312.81

0.00

312.81

Other Income

2.98

Operating Profit (PBDIT)

305.07

Interest

1.00

Exceptional Items

0.00

Gross Profit (PBDT)

610.22

Depreciation

0.00

Profit Before Tax

304.06

Tax

39.98

Provisions and contingencies

0.00

Profit After Tax

264.08

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

264.08

Share in Profit of Associates

0.00

Minority Interest

0.00

Other related items

0.00

Consolidated Net Profit

264.08

Equity Capital

0.00

Face Value

1.00

0.00

Reserves

1,857.29

Earnings per share (EPS)

1.08

Diluted Earnings per share

1.08

Operating Profit Margin (Excl OI)

40.77%

0.00

40.77%

Gross Profit Margin

41.04%

0.00

41.04%

PAT Margin

35.64%

0.00

35.64%

Public Share Holdings (%)

0.00

0.00%

Pledged Promotor Holding (%)

0.00

0.00%

Quarterly - Net Sales

Net Sales 74.10 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is 18.26% vs 16.88% in Jun 2025

YoY Growth in quarter ended Sep 2025 is 35.34% vs 30.54% in Sep 2024

Quarterly - Consolidate Net Profit

Consolidate Net Profit 26.41 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is 39.81% vs 29.47% in Jun 2025

YoY Growth in quarter ended Sep 2025 is 117.55% vs 28.33% in Sep 2024

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 30.21 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is 25.35% vs 27.11% in Jun 2025

YoY Growth in quarter ended Sep 2025 is 87.87% vs 24.94% in Sep 2024

Quarterly - Interest

Interest 0.10 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is -23.08% vs -13.33% in Jun 2025

YoY Growth in quarter ended Sep 2025 is -44.44% vs 260.00% in Sep 2024

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 40.77%

in Sep 2025

Figures in %

QoQ Growth in quarter ended Sep 2025 has improved from Jun 2025

YoY Growth in quarter ended Sep 2025 has improved from Sep 2024